HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

An indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer’s tafamidis in frontline ATTR-CM.

By Pharmaceutical Technology · May 12, 2026 · via Pharmaceutical Technology
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
pipelineformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Alkermes’ Lumryz clears phase 3 in idiopathic hypersomnia, intensifying Jazz rivalry
PipelineBriefing
Alkermes’ Lumryz clears phase 3 in idiopathic hypersomnia, intensifying Jazz rivalry
Three months post-Avadel acquisition, Alkermes’ Lumryz met all endpoints in the phase 3 Revitalyz study for id…
May 13, 2026
STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
PipelineSTAT News ↗
STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
Doctors have linked a boy's tumor to a gene therapy, but say the rare risks need to be weighed against the pro…
May 13, 2026
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
PipelineFierceBiotech ↗
Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, e…
May 12, 2026